Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a leading global medicinal cannabis company, has launched its new line of CBD-based acne and skin products, RAF FIVE™.
Developed in partnership with Harvard-trained and US board-certified cosmetic dermatologist Dr Karyn Grossman and noted drug development chemist Dr Brian Warrington, the RAF FIVE™ line of products consists of five acne treatments using a proprietary formulation incorporating CBD.
Entering an international acne medication market valued at more than US$11 billion, Zelira’s Dermatology subsidiary Ilera Derm LLC is developing several other topical products for launch in 2022, including anti-aging, sexual health/intimacy and specific skin conditions such as psoriasis.
Under-serviced skincare product market
“I am excited to announce the launch of Zelira’s Dermatology subsidiary and the RAF FIVE™ acne treatment line of skincare products," Zelira Therapeutics CEO and managing director Dr Oludare Odumosu said.
"Dr Grossman’s reputation and experience in the cosmetic dermatology industry, combined with Zelira’s peerless position in cannabinoid science, is the perfect combination.
“We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the US$11 billion acne treatment market where there is a high level of dissatisfaction with existing products and unmet needs.
"Zelira is staking a claim in the cannabinoid-based, over-the-counter skincare product market with our differentiated dermatology.”
Shares higher
Shares have been as much as 13.2% higher in the first hour of trading to A$0.043.
Available now in the United States, RAF FIVE™ is the only skincare line in the world to feature Zylorma™, a patent-pending acne-fighting complex developed by Zelira and Dr Grossman.
Zylorma™ uses a proprietary formulation with CBD, salicylic acid and additional botanical compounds to fight bacteria and clogged pores associated with acne and balance sebum production to help eliminate and prevent acne breakouts.
"New and unique solution for acne"
“I am thrilled to be a part of the new Ilera Derm and to have teamed up with Zelira to create Zylorma™ and the RAF FIVE™ skincare line,” Dr Karyn Grossman said,
“Zelira is already known as a leader in cannabinoid research and development for the medical cannabis market, so when they offered me the opportunity to use my medical expertise alongside their ground-breaking scientific formulations to create a truly new and unique solution for acne, I couldn’t pass it up.
“In my medical practice I’ve spent many years treating patients suffering from acne and have seen firsthand their struggle to find effective treatments, so I am so excited to see the results from our ongoing patient study and the marked improvement after using the RAF FIVE™ products.
"I believe that science has just started to skim the surface of the skin-healing properties of cannabinoids; RAF FIVE™ is only the beginning.”
Marked improvements
According to Zelira, the results from RAF FIVE™’s 28-day self-assessment survey of 45 participants showed marked improvements:
Zelira says it has also conducted rigorous industry standard consumer use study for its RAF FIVE™ franchise that showed improvement in all the participants during the 28-day study. Results showed significant improvement as early as seven days for some participants.
About the company
Zelira is a global biopharmaceutical company manufacturing and marketing cannabinoid-based medicines. It owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to access the world’s largest and fastest growing markets.
The company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.
Zelira recently expanded into the large and lucrative German CBD-market through a distribution partnership with Adjupharm, a German subsidiary of IM Cannabis Corp (CSE:IMCC).